Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with gemcitabine + cisplatin as neoadjuvant therapy followed by adjuvant durvalumab in resectable muscle-invasive bladder cancer
NL-OMON60217Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of durvalumab, gemcitabine and cisplatin in bladder cancer and transitional cell carcinoma (TCC), sponsored by AstraZeneca. Primary endpoints: pathological complete response and event-free survival. Started Apr 2019; status: active, not recruiting.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON60217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60217.